Back

Patterns of treatment and genetic testing in transthyretin amyloid cardiomyopathy: a real-world, multinational survey

29 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Perspectives in public health and cardiovascular diseases (1) Public Health ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Janice Chung

(United States of America)

2 More presentations in this session

Presentation thumbnail
A global analysis of women's participation in cardiovascular clinical trials from 2018 to 2024
Miss A. Lee (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Trends of health care costs of heart failure during implementation of SGLT2 inhibitors: Data from Finnish nationwide registers
Doctor M. Tarkia (Helsinki, FI)
Abstract Slides Video

Access the full session

Session thumbnail
Perspectives in public health and cardiovascular diseases (1)

The Event

Event poster

ESC Congress 2025

29 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) cardiogenomics: a tertiary centre experience
31 August 2025
thumbnail
Congress Presentation
Clinical presentation and treatment landscape of patients with transthyretin amyloidosis with cardiomyopathy: a real-world study in five European countries and Japan
18 May 2025
thumbnail
Congress Presentation
Impact of genetic testing family screening in hereditary transthyretin amyloidosis
30 August 2025
thumbnail
Congress Presentation
Utility of genetic testing for diagnosing hATTR patients: results from a European and Middle East genetic testing program
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources